12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Cimzia certolizumab pegol: Phase III started

UCB began the double-blind, international Phase III C-EARLY trial to compare subcutaneous Cimzia plus methotrexate vs. placebo plus methotrexate for 52 weeks in about 800 treatment-naïve patients with early, moderate to severe RA. Patients who achieve sustained remission with Cimzia at 52 weeks...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >